AnalystBook Research · Company Intelligence

IDEX CORP /DE/

IEXNYSE

Built from IDEX CORP /DE/'s own SEC filings · updates as new filings land · sources cited throughout

or browse all covered companies

IDEX delivered steady growth, higher profit, a 20% margin and strong free cash flow from specialized industrial and health-science products.

The read at a glance✓ Audited against SEC data
  • GrowthRevenue grew 5.8%OK
  • ProfitabilityNet income declined 4.3% to $483.2M from $505MWatch
  • Cash flowFree cash flow grew 2.3% to $616.8M from $603MOK
  • MarginsOperating margin contracted 49 bps to 20.23%Watch
  • AccountingHigh-margin engineered-products growthNote
  • Insiders2 purchases and 1 salesOK

Business

IDEX manufactures fluid, metering, fire and safety, scientific and optical products.

Where the revenue comes from

Fiscal 2025, as IDEX CORP /DE/ reports it. History and quarterly detail are in the app.

  • HST$1.5B
  • FMT$1.2B
  • FSDP$744.3M

Leadership changes

From IDEX CORP /DE/'s own filings, the day they're filed.

  • Akhil Mahendra · Chief Financial Officer · appointmenteff. 2025-05-30
  • Stephanie Disher · Directors · appointmenteff. 2025-02-21
  • David C. Parry · directors · departureeff. 2025-02-19

Latest filings

  • 8-K · Company announcement2026-09-03
  • 8-K · Company announcement2026-08-17
  • 8-K · Company announcement2026-07-29
  • 10-Q · Quarterly report2026-07-29
  • 8-K · Company announcement2026-05-08
In the full recordFree for 14 days
  • What changed🔒
  • Insider signal🔒
  • Growth quality🔒
  • Margins & accounting🔒
  • Capital allocation🔒
  • Real risks🔒
  • The long arc🔒
  • Company history🔒
  • The filings, readable — with what changed vs the prior year highlighted🔒
  • Full financial statements, industry-aware, sources cited throughout🔒
  • Forensic score history & components — the trend, not one year🔒
  • Ownership: insider buys/sells, clusters, activist stakes🔒
  • Ana — ask about IDEX CORP /DE/, every answer cited to the official filings🔒

Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.

14-day free trial, no credit card. For research purposes only; not investment advice.